Drug reference
elacestrant
Drug monograph
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
An oral selective estrogen receptor degrader (SERD) that degrades the estrogen receptor, blocking its signaling.
Indications
For ER-positive metastatic breast cancer patients with ESR1 mutation who have received a CDK4/6 inhibitor
Related guidelines
Other Unclassified drugs
Ask House about elacestrant
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Harrison 22e·Updated: 2026-05-10